World Lung Day: Advancing Equity Through Low-Dose Lung Cancer Screening With Brian Whang, MD

Advances in Detection and Treatment

Dr. Whang emphasized that low‑dose lung cancer screening has meaningfully reduced lung cancer mortality since its introduction. Early randomized studies demonstrated a greater than 20% reduction in lung cancer mortality through screening, validating its effectiveness.

Dr. Whang highlighted Connecticut’s experience as a case study: screening adoption rose from 6% of eligible patients to over 23%. This upward trend mirrors broader national improvements in screening uptake; however, adoption remains uneven across the country and continues to pose a challenge to maximizing the survival benefits of screening.

How Low‑Dose Lung Cancer Screening Works

This screening tool is described as:

• Minimally invasive, non‑contrast, and completed within minutes.
• Radiation exposure is low, comparable to a mammogram or roughly the equivalent of several transatlantic flights.
• Results are typically available within 24 hours, sometimes sooner, making it practical for integration into preventive care.

Dr. Whang was unequivocal: this type of screening deserves recognition as a preventive measure equivalent in importance to mammography or colonoscopy. “It’s got a proven track record, and lung cancer has the highest mortality of all cancers. It should really be part of the conversation,” he stressed.

Addressing Disparities in Access and Outcomes

Despite its demonstrable effectiveness, disparities remain. Dr. Whang cited data showing that minorities, including Asian Americans, are less likely to be screened or diagnosed at earlier stages. These inequities highlight the need for both policy‑ and community‑level solutions, including:

• Legislative Action: Connecticut has passed outreach legislation to target underserved populations.
• Mobile Screening Programs: Expanding access via mobile CT vans deployed to communities with limited healthcare infrastructure.
• Data‑Driven Criteria Updates: Emerging evidence shows that duration of smoking, not just intensity, is a significant driver of risk in certain groups. For instance, African American individuals may develop high‑risk disease after decades of lower‑intensity smoking—criteria not always captured under current screening guidelines. Updating eligibility requirements may help catch cancers earlier in these populations.

Dr. Whang underscored the urgency: “We found that among people who eventually get lung cancer, if we’d had that more liberalized approach toward screening, we would have potentially caught their cancers earlier.”

Non–Smoking‑Related Lung Cancer: The Unmined Frontier

While about 80% of lung cancers are attributable to smoking, 20% occur in non‑smokers. Notably, more than half of Asian American women diagnosed with lung cancer report no smoking history. This phenomenon is under active study, with investigations focusing on genetic, environmental, and behavioral factors. Dr. Whang predicted this area will expand rapidly over the next several years as clinicians and researchers work to prevent late diagnoses in this significant patient subset.

Looking Ahead

Dr. Whang’s principal goals for the near future include expanding community outreach, improving equitable access, and advancing research among non‑smoker patient populations. He hopes low‑dose lung cancer screening adoption continues rising until it becomes a default element of preventive care—routinely recommended, accessible, and normalized alongside other cancer screenings.

Call to Action for Oncology Teams

In closing, Dr. Whang urged colleagues to remain informed and proactive regarding screening eligibility:

• Current US Preventive Services Task Force (USPSTF) criteria: ages 50–80 with a 20 pack‑year history, defined as one pack per day for 20 years, who either currently smoke or quit within the past 15 years.
• Dr. Whang anticipates eventual guideline evolution toward duration‑based criteria (years smoked, regardless of volume), already endorsed by some professional groups like the American Cancer Society.

His message to interdisciplinary colleagues: “Be conversant with it. Know the criteria and talk with your patients about it. This is a proven tool to save lives.”

Key Takeaways

• Low‑dose lung cancer screening reduces lung cancer mortality by over 20% and is safe, quick, and accessible.
• Adoption rates are improving in the U.S., with Connecticut rising from 6% to over 23% of eligible patients screened.
• Lung cancer accounts for the highest cancer mortality—reinforcing the imperative for preventive screening.
• Disparities persist, especially among racial/ethnic minorities and underserved populations. Policy, outreach, and mobile screening initiatives are addressing these gaps.
• Non‑smokers remain at risk (20% of cases), particularly Asian American women. Studies are ongoing to identify biological and environmental drivers.
• Guidelines may evolve: emphasis is shifting from smoking intensity to smoking duration as a more accurate predictor of risk.
• Teamwide responsibility: Physicians, nurses, pharmacists, and allied health professionals should be fluent in criteria and proactive in patient education.

About Dr. Whang

Brian Whang, MD, FACS, is the Medical Director of Lung Cancer Screening and Director of Thoracic Surgery for Hartford Healthcare’s Fairfield Region. He is a Thoracic Surgeon at St. Vincent’s Medical Center in Bridgeport, Connecticut, where he specializes in treating diseases affecting the chest, lungs, esophagus, and heart. Dr. Whang’s research interest revolves around thoracic oncology, where he is passionate about developing and offering new surgical solutions and advocacy for better lung cancer screening guidelines.